Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis
Article first published online: 2 OCT 2003
Alimentary Pharmacology & Therapeutics
Volume 11, Issue 6, pages 1053–1057, November 1997
How to Cite
GIONCHETTI, P., RIZZELLO, F., VENTURI, A., BRIGNOLA, C., FERRETTI, M., PERUZZO, S. and CAMPIERI, M. (1997), Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Alimentary Pharmacology & Therapeutics, 11: 1053–1057. doi: 10.1046/j.1365-2036.1997.00259.x
- Issue published online: 2 OCT 2003
- Article first published online: 2 OCT 2003
- Cited By
Mesalazine suppositories at 500 mg b.d. are a safe and effective treatment for patients with ulcerative proctitis or distal proctosigmoiditis. Recently a mesalazine 1 g suppository (Pentasa) has been developed.
Fifty patients with active ulcerative colitis extending not beyond 20 cm from the anus on sigmoidoscopy, participated in a randomized single-blind study comparing the efficacy, tolerance and acceptance of the new Pentasa mesalazine 1 g suppository, given once daily versus Claversal mesalazine 500 mg suppository b.d.
After 2 weeks, clinical remission was observed in 16 of 25 (64%) in the Pentasa group and in 7 of 25 (28%) in the Claversal 500 mg b.d. treated group; sigmoidoscopic remission occurred in 13 of 25 (52%) in the Pentasa group and in six of 25 (24%) in the Claversal group (P < 0.01). After 4 weeks, clinical and sigmoidoscopic remission were observed, respectively, in 84 and 76% of patients treated with Pentasa suppositories, and in 80 and 72% of patients treated with Claversal suppositories 500 mg b.d. (P= N.S.). The patients' evaluation for tolerability and practicality showed that the Pentasa suppository was significantly superior to the Claversal suppository.
Pentasa 1 g suppository once daily induces a quicker clinical and sigmoidoscopic remission, and was better tolerated, than the Claversal 500 mg suppository b.d., and it may represent an advance for the topical treatment of distal proctosigmoiditis.